Group 1C: Triple Negative Breast Cancer; Immunology



Wednesday, Dec 14
10:00 am – 11:30 am Eastern Time (US/New York)



Poster #P3-06-03

Trilaciclib induces immune changes within the tumor microenvironment in early-stage triple negative breast cancer

Poster #P1-04-04:

A multiomic approach to the identification of immune signatures of anti-PD1/PDL1 therapy responders in metastatic triple negative breast cancer: new implications in the role of helper T-cell and B-cell interplay

Poster author Avia Wilkerson, M.D. will attend this session

Mentor: Marlena Murphy

In 2018, Marlena Murphy was diagnosed with stage III triple-negative breast cancer. In 2019, as a patient advocate, she attended the San Antonio Breast Cancer Symposium. After that, Marlena attended virtual GRASP sessions in 2020 and 2021 as a patient advocate. As a result of being a GRASP participant, in 2021 Marlena submitted feedback for an article on GRASP for Cancer Therapy Advisor, an online news source. She also received a recommendation and offer to serve as a volunteer on the Emory Winship Cancer Institute Patient and Family Advisory (PFA) Council. Because of Marlena’s commitment to advocacy and seeking knowledge beyond the realm of breast cancer, she was offered a position as a program manager with GRASP in 2021. Now, she serves as an enthusiastic team member, bringing together cancer researchers and advocates to exchange ideas and learn from each other. She continues to provide constructive feedback to cancer researchers from a patient’s perspective. She also works as a Community Advocate for Turning Point Breast Cancer Rehabilitation. Marlena’s role as a patient advocate was one she did not plan on during her lifetime, yet, she accepted it and decided that her diagnosis would not be in vain. Marlena is a mother to a teenage daughter and enjoys helping others. As a result of her diagnosis and desire to help people, Marlena entered grad school in 2020 to become a Clinical Mental Health Counselor. Marlena plans to use the degree to provide pro bono therapy for breast cancer patients and survivors.

Twitter: @MarlenaDM

Scientist: Amanda Jacobson, Ph.D.

Amanda Jacobson obtained a Ph.D. in cell biology and immunology from the University of Utah, and her post-doctoral work focused on HIV pathogenesis and infant immunology. She has been in the biotech/ pharma space supporting oncology drug development in both blood and solid tumor indications for a little over 10 years. Currently, she is the director of clinical science at a small biotech company supporting clinical trials in breast cancer.